NEW YORK (Reuters Health) – Results of a study conducted in Singapore indicate that vasopressin administered to patients in prolonged cardiac arrest does not improve survival to hospital…
NEW YORK (Reuters Health) – In high-risk hypertensive patients with or without prior coronary artery disease, adding the angiotensin receptor II blocker valsartan to conventional non-ARB treatment reduces…
NEW YORK (Reuters Health) – Two independent studies have shown that reduced-activity variants of the cytochrome P450 2D6 (CYP2D6) enzyme are not associated with poorer disease control in…
NEW YORK (Reuters Health) – The lipid-modifying effects of rosuvastatin (Crestor: AstraZeneca) are stronger than atorvastatin (Lipitor; Pfizer) in patients with an acute coronary syndrome (ACS), according to…
NEW YORK (Reuters Health) – The reduced risk of developing invasive breast cancer with adjuvant tamoxifen therapy after lumpectomy and radiation for ductal carcinoma in situ (DCIS) is…
NEW YORK (Reuters Health) – When antiepileptic drug therapy fails to control disabling temporal lobe epilepsy adequately, patients have a much better chance of becoming seizure free with…
NEW YORK (Reuters Health) – A new analysis of pooled data on omalizumab should help allay concerns that omalizumab (Xolair; Genentech, Novartis) may increase the risk for cancer.…
NEW YORK (Reuters Health) – Iron-deficiency anemia can lead to high glycosylated hemoglobin (HbA1c) concentrations that do not reflect glycemic parameters, an Indian study has shown. “The use…
NEW YORK (Reuters Health) – In patients with type 2 diabetes, glycemic control is better and weight loss is sustained up to 84 weeks with exenatide once weekly…
NEW YORK (Reuters Health) – Malnourished adults aged 60 and older who started an energy- and protein-enriched nutritional plan plus calcium and vitamin D supplements following hospital discharge…
